ReviewAmerican journal of respiratory and critical care medicine2021
Severe Adult Asthmas: Integrating Clinical Features, Biology, and Therapeutics to Improve Outcomes.
Review in American journal of respiratory and critical care medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 80 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Individualizing Treatment for Asthma in Primary Care
Individualizing Treatment for Asthma in Primary Care (Full Study)
Who cites it
80 citing papers in PubMed, 1 synthesis or guideline pooled it, 134 citations in OpenAlex.
- Phagocytic aberrations in macrophages in asthma: a mechanistic systematic review integratingFrontiers in immunology · 2026Pooled it
- Dupilumab Efficacy in Patients with Type 2 Asthma with and without Elevated Blood Neutrophils.Journal of immunology research · 2023Trial
- Evolution, hotspots, and future directions of artificial intelligence in asthma research: a Web of Science-based bibliometric analysis [2016-2026].Journal of thoracic disease · 2026Article
- Fueling the fire: metabolic dysfunction and senescence as drivers of lung aging and disease.Physiological reviews · 2026Review
- Effectiveness and Safety of Budesonide/Formoterol in Asthma: A Systematic Review.Healthcare (Basel, Switzerland) · 2026Review
- Targeting CD30L Alleviates Airway Remodeling via JNK/p38 MAPK Pathway in OVA-Induced Asthmatic Mice.Allergy, asthma & immunology research · 2026Article
- The Architecture of Deep Phenotyping in Asthma: Integrating Molecular, Metabolic, and Neuro-Hormonal Endotypes.International journal of molecular sciences · 2026Review
- Itaconate Modulates Neutrophil Homeostasis to Ameliorate Airway Inflammation in Diesel Exhaust Particles-exacerbated Asthma via Inhibiting NETs Formation.International journal of biological sciences · 2026Article
- Nasal Microbiota Associated with the Lung Radiomic Features in Asthma.International journal of general medicine · 2026Article
- Precision Medicine Advances in Chronic Lung Diseases.International journal of molecular sciences · 2025Article
- Multi-omics identifies severe asthma endotypes linked toThe World Allergy Organization journal · 2025Article
- Impact of clinical factors and season on inflammatory cytokines in biologic-treated and untreated asthma.Respiratory research · 2025Article
- MSCs attenuate airway remodeling in HDM-induced asthma by inhibiting the Timp1-Wnt2b axis.Acta biochimica et biophysica Sinica · 2025Article
- Dual roles of amino acid metabolic reprogramming in chronic airway diseases and lung cancer: therapeutic opportunities and challenges.World journal of surgical oncology · 2025Review
- Mulberroside A ameliorates murine allergic airway inflammation by suppressing Th2 response and oxidative stress.Inflammopharmacology · 2025Article
- Targeting ADAM17 to dampen dendritic cell-mediated type 2 immune responses and airway inflammation associated with allergic asthma.Scientific reports · 2025Article
- Predicting 30-day in-hospital mortality in ICU asthma patients: a retrospective machine learning study with external validation.BMC pulmonary medicine · 2025Article
- The role of mesenchymal stem cell‑derived exosomes in asthma (Review).Molecular medicine reports · 2025Review
- CD8+ TEMRAs in severe asthma associate with asthma symptom duration and escape proliferation arrest.JCI insight · 2025Article
- Key role of thymic stromal lymphopoietin as a molecular target for biologic treatment of severe asthma.Frontiers in allergy · 2025Review
20 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Evaluation and effective management of asthma, and in particular severe asthma, remains at the core of pulmonary practice. Over the last 20-30 years, there has been increasing appreciation that "severe asthma" encompasses multiple different subgroups or phenotypes, each with differing presentations. Using clinical phenotyping, in combination with rapidly advancing molecular tools and targeted monoclonal antibodies (human knockouts), the understanding of these phenotypes, and our ability to treat them, have greatly advanced. Type-2 (T2)-high and -low severe asthmas are now easily identified. Fractional exhaled nitric oxide and blood eosinophil counts can be routinely employed in clinical settings to identify these phenotypes and predict responses to specific therapies, meeting the initial goals of precision medicine. Integration of molecular signals, biomarkers, and clinical responses to targeted therapies has enabled identification of critical molecular pathways and, in certain phenotypes, advanced them to near-endotype status. Despite these advances, little guidance is available to determine which class of biologic is appropriate for a given patient, and current "breakthrough" therapies remain expensive and even inaccessible to many patients. Many of the most severe asthmas, with and without T2-biomarker elevations, remain poorly understood and treated. Nevertheless, conceptual understanding of "the severe asthmas" has evolved dramatically in a mere 25 years, leading to dramatic improvements in the lives of many.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.